United States Pneumococcal Vaccination Market was valued at USD 2.5 Billion in 2022 and is projected to reach USD 3.7 Billion by 2030, growing at a CAGR of 5.4% from 2024 to 2030.
The U.S. pneumococcal vaccination market is experiencing significant growth, driven by increased awareness, aging demographics, and advancements in vaccine technology. As of 2024, the market was valued at approximately $5.24 billion, with projections suggesting it will reach $6.51 billion by 2034, reflecting a compound annual growth rate (CAGR) of 2.3% during this period. This growth is largely attributed to heightened public health initiatives and the introduction of new, more effective vaccines.
Recent developments have further propelled the market's expansion. In June 2024, the FDA approved CAPVAXIVE, a 21-valent conjugate pneumococcal vaccine developed by Merck. This vaccine offers protection against 21 strains of the pneumococcal bacteria, addressing a broader range of infections compared to previous vaccines. Its approval has intensified competition among pharmaceutical companies, leading to continuous improvements in vaccine efficacy and coverage.
Moreover, Vaxcyte, a biotech startup, has emerged as a formidable competitor with its experimental vaccine, VAX-31. In early-stage trials, VAX-31 demonstrated superior immune responses against 18 of the 20 strains targeted, surpassing the performance of Pfizer's Prevnar 20. These promising results position VAX-31 as a potential game-changer in pneumococcal disease prevention, challenging the market dominance of established players like Pfizer and Merck.
In September 2024, Vaxcyte's shares surged by over 40% following the release of positive trial data for VAX-31. The vaccine exhibited a favorable safety profile and elicited strong immune responses across multiple serotypes. Vaxcyte plans to initiate Phase 3 trials in mid-2025, aiming to further validate the vaccine's efficacy and accelerate its path to market. This development has heightened investor interest and underscores the dynamic nature of the pneumococcal vaccine market.
In response to these advancements, U.S. health officials have updated vaccination guidelines. The Advisory Committee on Immunization Practices now recommends that individuals aged 50 and older receive pneumococcal vaccinations, lowering the previous recommendation age from 65. This change aims to better protect a broader segment of the population, particularly as pneumococcal infections remain a significant public health concern, with over 30,000 cases of invasive pneumococcal disease reported annually in the U.S.
The market's growth is also supported by favorable government initiatives and funding. Public health campaigns and government programs play a crucial role in administering and distributing pneumococcal vaccines, ensuring they meet safety and efficacy standards. Financial support, including subsidies and reimbursement schemes, enhances vaccine accessibility and affordability, contributing to increased vaccination rates.
Advancements in vaccine technology have led to the development of vaccines targeting a wider array of pneumococcal strains. The introduction of vaccines like CAPVAXIVE and VAX-31 reflects the industry's commitment to addressing the evolving landscape of pneumococcal infections. These innovations offer hope for more comprehensive protection against pneumococcal diseases, potentially reducing the incidence of infections and associated healthcare costs.
However, challenges remain in achieving widespread vaccine coverage. Despite the availability of effective vaccines, a segment of the population remains unvaccinated due to factors such as vaccine hesitancy, logistical barriers, and socioeconomic constraints. Ongoing public health efforts are essential to educate the public about the benefits of vaccination and to address concerns that may hinder vaccine uptake.
Looking ahead, the U.S. pneumococcal vaccination market is poised for continued growth. The convergence of innovative vaccine development, supportive government policies, and evolving public health recommendations creates a dynamic environment for vaccine manufacturers and healthcare providers. As new vaccines enter the market and existing ones receive updates, patients stand to benefit from more effective and comprehensive protection against pneumococcal diseases.
Get an In-Depth Research Analysis of the US Pneumococcal Vaccination Market Size And Forecast [2025-2032]
Pfizer
GSK
MSD
CDIBP
WALVAX
Sinovac
Bio Kangtai
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the US Pneumococcal Vaccination Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the US Pneumococcal Vaccination Market
Conjugate Vaccines
Polysaccharide Vaccines
Pediatric Population
Adult Population
Intramuscular Injection
Subcutaneous Injection
Hospitals
Clinics
Pharmacies
Direct Procurement
Retail Pharmacies
Online Pharmacies
US (United States, US and Mexico)
Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
South America (Brazil, Argentina, Columbia, etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
For More Information or Query, Visit @ Pneumococcal Vaccination Market Research Analysis
1. Introduction of the US Pneumococcal Vaccination Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. US Pneumococcal Vaccination Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. US Pneumococcal Vaccination Market, By Type
6. US Pneumococcal Vaccination Market, By Application
7. US Pneumococcal Vaccination Market, By Geography
US
Europe
Asia Pacific
Rest of the World
8. US Pneumococcal Vaccination Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading US Research and Consulting firm servicing over 5000+ US clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/